Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF

Autor: Tor Biering-Sørensen, M. Lund, Eileen O'Meara, Stephen B. Heitner, Jindrich Spinar, Marco Metra, Shin-ichi Momomura, Michael Böhm, Diana Bonderman, Piotr Ponikowski, Jose H. Flores-Arredondo, James C. Fang, Siddique Abbasi, Scott D. Solomon, John R. Teerlink, Galactic-Hf Investigators, Fady I. Malik, Brian Claggett, Stuart Kupfer, John J.V. McMurray, Rafael Diaz, David E Lanfear, G. Michael Felker

Publikováno v: GALACTIC HF Investigators 2021, ' Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF ', American College of Cardiology. Symposia, vol. 78, no. 2, pp. 97-108 . https://doi.org/10.1016/j.jacc.2021.04.065

Background: \ud In GALACTIC-HF (Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure) (n = 8,256), the cardiac myosin activator, omecamtiv mecarbil, significantly reduced the primary composite endpoint

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b84d6e24d7eb47364ec58d9abf4b90b0
https://curis.ku.dk/portal/da/publications/effect-of-ejection-fraction-on-clinical-outcomes-in-patients-treated-with-omecamtiv-mecarbil-in-galactichf(0f84e619-bf1b-467d-9304-c8908158c15d).html

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

Autor: Alexandra Arias-Mendoza, Felix J. A. Ramires, Karen Sliwa, Tor Biering-Sørensen, Vyacheslav Mareev, Pranas Šerpytis, Rafael Diaz, Jonathan G. Howlett, Assen Goudev, Eileen O'Meara, Cândida Fonseca, Christopher E. Kurtz, Scott D. Solomon, Kirkwood F. Adams, Eva Goncalvesova, Luis E. Echeverría Correa, Diana Bonderman, John R. Teerlink, Michael Böhm, M. Lund, Galactic-Hf Investigators, Fady I. Malik, Jason C. Legg, María G. Crespo-Leiro, Ulf Dahlström, Lucie Sharpsten, Alexander Parkhomenko, Piotr Ponikowski, Peter S. Macdonald, James C. Fang, Ramón Corbalán, Thomas M. Suter, Mehmet Yilmaz, Gerasimos Filippatos, Jindrich Spinar, Hans Vandekerckhove, Shin-ichi Momomura, Faiez Zannad, János Tomcsányi, Adriaan A. Voors, G. Michael Felker, Inder S. Anand, John J.V. McMurray, Siddique Abbasi, Dragos Vinereanu, David E Lanfear, Claire Varin, John G.F. Cleland, Marco Metra

Publikováno v: European Journal of Heart Failure, 22(11), 2160-2171. Wiley
Teerlink, J R, Diaz, R, Felker, G M, McMurray, J J V, Metra, M, Solomon, S D, Adams, K F, Anand, I, Arias-Mendoza, A, Biering-Sorensen, T, Bohm, M, Bonderman, D, Cleland, J G F, Corbalan, R, Crespo-Leiro, M G, Dahlstrom, U, Echeverria Correa, L E, Fang, J C, Filippatos, G, Fonseca, C, Goncalvesova, E, Goudev, A R, Howlett, J G, Lanfear, D E, Lund, M, Macdonald, P, Mareev, V, Momomura, S, O'Meara, E, Parkhomenko, A, Ponikowski, P, Ramires, F J A, Serpytis, P, Sliwa, K, Spinar, J, Suter, T M, Tomcsanyi, J, Vandekerckhove, H, Vinereanu, D, Voors, A A, Yilmaz, M B, Zannad, F, Sharpsten, L, Legg, J C, Abbasi, S A, Varin, C, Malik, F I, Kurtz, C E & GALACTIC HF Investigators 2020, ' Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction : GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials ', European Journal of Heart Failure, vol. 22, no. 11, pp. 2160-2171 . https://doi.org/10.1002/ejhf.2015
Eur J Heart Fail
European journal of heart failure, Hoboken : John Wiley and Sons Ltd, 2020, vol. 22, iss. 11, p. 2160-2171
European Journal of Heart Failure
European Journal of Heart Failure, 2020, 22 (11), pp.2160-2171. ⟨10.1002/ejhf.2015⟩
RUC: Repositorio da Universidade da Coruña
Universidade da Coruña (UDC)
RUC. Repositorio da Universidade da Coruña
instname

Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Throug

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f000e290f8ad64a47f31d4c9a07593e9
https://research.rug.nl/en/publications/1dc2cc6b-2c2d-4680-b6c8-a27ff9da2c76

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.